Detailed Information on Publication Record
2003
Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer
SKŘIČKOVÁ, Jana, Lenka BABIČKOVÁ, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PALKOVA et. al.Basic information
Original name
Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer
Authors
SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor), Lenka BABIČKOVÁ (203 Czech Republic), Jana KAPLANOVÁ (203 Czech Republic), Olga KUBOVÁ (203 Czech Republic), Ivana PALKOVA (203 Czech Republic) and Marcela TOMÍŠKOVÁ (203 Czech Republic)
Edition
Madrid, Spain, Woorkbook of Iressa Clinical Experience Meeting, p. 58-58, 2003
Publisher
AstraZeneca
Other information
Language
English
Type of outcome
Stať ve sborníku
Field of Study
30203 Respiratory systems
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/03:00008833
Organization unit
Faculty of Medicine
Keywords in English
non-small-cell lung cancer; gefitinib treatment; survival rate
Změněno: 31/7/2003 10:48, prof. MUDr. Jana Skřičková, CSc.
Abstract
V originále
Forty-five patients with non-small-cell lung cancer underwent treatment with gefitinib; 51% of them had prior radiotherapy. Treatment duration was 1 to 14 months (median, 3 months). Diseased progressed in 18 patients within 3 months, but stabilised in 27 patients for longer than 3 months. Disease-related symptoms were generally milder after gefitinib treatment.
Links
| MSM 141100003, plan (intention) |
|